Begin a Phase 3 trial of VS-7375 in first-line metastatic pancreatic cancer

Deadline not yet reached (65 days left)

Announced: 14 Oct 2026
Due: 31 Dec 2026

Deadline
Met
Late
Not met
Today

What the company said

“rapidly towards a Phase 3 trial in metastatic pancreatic cancer in the first-line setting, which is expected to begin later this year”

SourceVerastem, Inc. Form 8-K press release, 2026-10-14
FilingSEC filing index
Deadline as statedlater this year
Deadline used31 Dec 2026, the last day of the stated period
TypeProject
Permanent referenceKI-C-2026-VSTM-010735
Cite as https://keptindex.org/c/KI-C-2026-VSTM-010735/ — this address never changes.

What we found

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Begin
Deliverable: Phase 3 trial of VS-7375 in first-line metastatic pancreatic cancer
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: Medium

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Verastem, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2026-VSTM-010735 · Corrections policy